Comparative susceptibilities of Klebsiella species, Enterobacter species, and Pseudomonas aeruginosa to 11 antimicrobial agents in a tertiary- care university hospital

American Journal of Medicine

Volumn 100, Issue 6 A, 1996, Pages 20S-25S

  Fekete, Thomas ^a   Tumah, Haitham ^a   Woodwell, John ^a   Satishchandran, Vilas ^a   Truant, Allan ^a   Axelrod, Peter ^a  

^a Temple University Health Sciences Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFEPIME; CEFOPERAZONE; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN; TIMENTIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; CONFERENCE PAPER; ENTEROBACTER; ENTEROBACTER INFECTION; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; KLEBSIELLA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STRAIN DIFFERENCE; UNIVERSITY HOSPITAL; ANTIBIOTIC RESISTANCE; ARTICLE; COMPARATIVE STUDY; CROSS INFECTION; DRUG ANTAGONISM; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; STATISTICS; UNITED STATES;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; ENTEROBACTER; ENTEROBACTERIACEAE INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; KLEBSIELLA; KLEBSIELLA INFECTIONS; MICROBIAL SENSITIVITY TESTS; PHILADELPHIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 0030600079     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infections. Am J Med. 1991;91(suppl 3B):72S-75S.
2. Sanders CC, Sanders WE. Clinical importance of inducible β-lactamases in gram-negative bacteria. Eur J Clin Microbiol. 1987;6:435.
3. Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother. 1990;34:2193.
4. Toye BW, Scriver SR, Low DE, and the Canadian Antimicrobial Resistance Group. Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother. 1993;32:81-86.
5. Fuchs PC, Jones RN, Barry AL, et al. In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates. Diagn Microbiol Infect Dis. 1986;5:345-349.
6. Thornsberry C, Brown SD, Yee YC, Bouchillon SK, Marler JK, Rich T. In-vitro activity of cefepime and other antimicrobials: survey of European isolates. J Antimicrob Chemother. 1993;32(suppl B):31-53.
7. Fung-Tomc J, Dougherty TJ, DeOrio FJ, Simich-Jacobson V, Kessler RE. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to β-lactamase levels. Antimicrob Agents Chemother. 1989;33:498-502.
8. Neu HC, Chin NX, Jules K, Labthavikul P. The activity of BMY 28142 a new broad spectrum β-lactamase stable cephalosporin. J Antimicrob Chemother. 1986;17:441-452.
9. Kessler RE, Fung-Tomc J. Susceptibility of bacterial isolates to β-lactam antibiotics from U.S. clinical trials over a 5-year period. Am J Med. 1996;100(suppl 6A):13S-19S.
10. Gradelski E, Fung-Tomc J, Huczko E, Kessler RE. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations. J Antimicrob Chemother. 1993;32(suppl B):75-80.
11. Hancock REW, Bellido F. Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother. 1992;29(suppl A):1-6.
12. Giamarellou H, Sahin A, Chryssouli Z. Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus other β-lactams against multiresistant gram-negative isolates. Drugs Exp Clin Res. 1987;13:149-153.
13. Giamarellou H. Low-dosage cefepime as treatment for serious bacterial infections. J Antimicrob Chemother. 1993;32(suppl B):123-132.
14. Mouton Y, Chidiac C, Humbert G, et al. A non-comparative, multicentre study of cefepime in the treatment of serious bacterial infections. J Antimicrob Chemother, 1993;32(suppl B):133-140.
15. National Committee for Clinical Laboratory Standards. Method for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 2nd ed. Approved Standard. Villanova, PA: NCCLS; 1990. Document M7-42.
16. Steers E, Foltz EL, Graves BS. An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics. Antibio Chemother. 1959;9:307-311.
17. Gustaferro CA, Steckelberg JM. Cephalosporin antimicrobial agents and related compounds. Mayo Clin Pro. 1991;66:1064-1073.
18. Jones RN, Marshall SA. Antimicrobial activity of cefepime tested against Bush group I β-lactamase-producing strains resistant to ceftazidime: a multi laboratory national and international clinical isolate study. Diagn Microbiol Infect Dis. 1994;19:33-38.
19. Hoepelman AIM, Kieft H, Aoun M, et al. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. J Antimicrob Chemother. 1993;32(suppl B):175-186.